Combigan

Migraine, Open-angle glaucoma, Migraine Disorders + 6 more

Treatment

20 Active Studies for Combigan

What is Combigan

Timolol

The Generic name of this drug

Treatment Summary

Brimonidine is a drug used to treat glaucoma and can be used to reduce facial redness associated with rosacea. It is a type of alpha-adrenergic agonist, which works by reducing the amount of fluid in the eye and increasing the drainage of fluid. Brimonidine is considered to be a safer alternative to beta-blockers, as it does not have significant cardiovascular side effects. It was approved by the FDA in 1996 and was later approved as Mirvaso in 2013 for rosacea treatment.

Timoptic

is the brand name

image of different drug pills on a surface

Combigan Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Timoptic

Timolol

1978

167

Effectiveness

How Combigan Affects Patients

Brimonidine is an alpha-2 adrenergic receptor agonist, which means it is designed to target and activate the alpha-2 adrenergic receptor. This helps reduce the risk of side effects such as low blood pressure, slow heart rate, and drowsiness. Brimonidine also reduces the chances of unwanted eye effects caused by alpha-1 receptors, like blanching, pupil dilation, and eyelid retraction. After two hours, brimonidine helps reduce eye pressure, and can maintain this effect for up to a year. Additionally, it can reduce inflammation and redness in the skin, and may even have neuro

How Combigan works in the body

Brimonidine is commonly used to treat glaucoma and facial redness. In the eye, it works by activating alpha-2 adrenoceptors, which reduces norpinephrine activity, decreases aqueous humor production, and increases uveoscleral outflow. This helps to lower intraocular pressure which reduces the risk of vision loss. When applied topically to the skin, brimonidine constricts blood vessels, reducing redness and inflammation. This makes it effective for treating facial redness caused by rosacea.

When to interrupt dosage

The recommended dose of Combigan is contingent upon the identified condition, including Open Angle Glaucoma, facial erythema and Ocular Hypertension. The extent of dosage changes as per the technique of delivery featured in the table below.

Condition

Dosage

Administration

Migraine Disorders

5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL

Ophthalmic, Solution - Ophthalmic, Solution, , Oral, Tablet, Tablet - Oral, Solution / drops - Ophthalmic, Solution / drops, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid - Ophthalmic, Suspension / drops, Suspension - Ophthalmic, Suspension, Suspension / drops - Ophthalmic, Liquid, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic

Open-angle glaucoma

5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL

Ophthalmic, Solution - Ophthalmic, Solution, , Oral, Tablet, Tablet - Oral, Solution / drops - Ophthalmic, Solution / drops, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid - Ophthalmic, Suspension / drops, Suspension - Ophthalmic, Suspension, Suspension / drops - Ophthalmic, Liquid, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic

Migraine

5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL

Ophthalmic, Solution - Ophthalmic, Solution, , Oral, Tablet, Tablet - Oral, Solution / drops - Ophthalmic, Solution / drops, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid - Ophthalmic, Suspension / drops, Suspension - Ophthalmic, Suspension, Suspension / drops - Ophthalmic, Liquid, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic

inadequate response to other therapeutic measures

5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL

Ophthalmic, Solution - Ophthalmic, Solution, , Oral, Tablet, Tablet - Oral, Solution / drops - Ophthalmic, Solution / drops, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid - Ophthalmic, Suspension / drops, Suspension - Ophthalmic, Suspension, Suspension / drops - Ophthalmic, Liquid, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic

insufficient response to beta-blockers

5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL

Ophthalmic, Solution - Ophthalmic, Solution, , Oral, Tablet, Tablet - Oral, Solution / drops - Ophthalmic, Solution / drops, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid - Ophthalmic, Suspension / drops, Suspension - Ophthalmic, Suspension, Suspension / drops - Ophthalmic, Liquid, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic

requiring adjunctive or replacement therapy

5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL

Ophthalmic, Solution - Ophthalmic, Solution, , Oral, Tablet, Tablet - Oral, Solution / drops - Ophthalmic, Solution / drops, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid - Ophthalmic, Suspension / drops, Suspension - Ophthalmic, Suspension, Suspension / drops - Ophthalmic, Liquid, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic

Glaucoma

5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL

Ophthalmic, Solution - Ophthalmic, Solution, , Oral, Tablet, Tablet - Oral, Solution / drops - Ophthalmic, Solution / drops, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid - Ophthalmic, Suspension / drops, Suspension - Ophthalmic, Suspension, Suspension / drops - Ophthalmic, Liquid, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic

Open Angle Glaucoma

5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL

Ophthalmic, Solution - Ophthalmic, Solution, , Oral, Tablet, Tablet - Oral, Solution / drops - Ophthalmic, Solution / drops, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid - Ophthalmic, Suspension / drops, Suspension - Ophthalmic, Suspension, Suspension / drops - Ophthalmic, Liquid, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic

Ocular Hypertension

5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL

Ophthalmic, Solution - Ophthalmic, Solution, , Oral, Tablet, Tablet - Oral, Solution / drops - Ophthalmic, Solution / drops, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid - Ophthalmic, Suspension / drops, Suspension - Ophthalmic, Suspension, Suspension / drops - Ophthalmic, Liquid, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic

Warnings

Combigan Contraindications

Condition

Risk Level

Notes

Lung Diseases, Obstructive

Do Not Combine

Sinus Bradycardia

Do Not Combine

Shock, Cardiogenic

Do Not Combine

Atrioventricular Block

Do Not Combine

Asthma

Do Not Combine

Heart Failure

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Timolol may interact with Pulse Frequency

There are 20 known major drug interactions with Combigan.

Common Combigan Drug Interactions

Drug Name

Risk Level

Description

4-Bromo-2,5-dimethoxyphenethylamine

Major

The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Timolol.

4-Methoxyamphetamine

Major

The therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Timolol.

Abediterol

Major

Timolol may decrease the bronchodilatory activities of Abediterol.

Adrafinil

Major

The therapeutic efficacy of Adrafinil can be decreased when used in combination with Timolol.

Agrostis gigantea pollen

Major

The risk of a hypersensitivity reaction to Agrostis gigantea pollen is increased when it is combined with Timolol.

Combigan Toxicity & Overdose Risk

The toxic dose of brimonidine in mice is 50 mg/kg, and in rats it is 100 mg/kg. Overdosing on brimonidine can cause low blood pressure, weakness, vomiting, drowsiness, slow heart rate, abnormal heart rhythms, narrowed pupils, difficulty breathing, low body temperature, and seizures. Treatment for a brimonidine overdose includes supportive care. Based on animal studies, brimonidine was not found to cause birth defects or fertility problems. It is not recommended to use brimonidine in pregnant or breastfeeding women, infants under the age of 2, or pediatric patients under the age of 18.

image of a doctor in a lab doing drug, clinical research

Combigan Novel Uses: Which Conditions Have a Clinical Trial Featuring Combigan?

114 active trials are underway to assess the potential of Combigan in providing relief from Open Angle Glaucoma, inadequately controlled intraocular pressure and Open Angle Glaucoma.

Condition

Clinical Trials

Trial Phases

Open-angle glaucoma

45 Actively Recruiting

Phase 2, Not Applicable, Phase 3, Phase 4, Early Phase 1, Phase 1

Open Angle Glaucoma

10 Actively Recruiting

Phase 3, Not Applicable, Phase 4

Ocular Hypertension

10 Actively Recruiting

Phase 3, Phase 1, Phase 2, Not Applicable, Phase 4

requiring adjunctive or replacement therapy

0 Actively Recruiting

inadequate response to other therapeutic measures

0 Actively Recruiting

Migraine Disorders

1 Actively Recruiting

Phase 3

Migraine

50 Actively Recruiting

Phase 4, Not Applicable, Phase 1, Phase 3, Phase 2, Early Phase 1

Glaucoma

0 Actively Recruiting

insufficient response to beta-blockers

0 Actively Recruiting

Combigan Reviews: What are patients saying about Combigan?

5

Patient Review

7/8/2015

Combigan for Wide-Angle Glaucoma

My eyes are very red, is this normal? Should I seek additional treatment for the redness?

5

Patient Review

7/1/2020

Combigan for Increased Pressure in the Eye

I have experienced some weight gain and swelling in my extremities since starting this medication, but it has been effective in keeping my blood pressure low. I take Lantus at night and Novolog 2x per day.

5

Patient Review

6/29/2018

Combigan for Increased Pressure in the Eye

I started with an IOP of 30 in each eye. My doctor prescribed Latanoprost once daily in each eye, but after a month there was no effect. They switched me to Combigan, and after 3 weeks of using it 2X per day my IOP was down to 19 in each eye. I introduced 1 drop in each eye in the morning, and again in the evening about 12 hours later, and that did the trick!

4

Patient Review

8/4/2016

Combigan for Increased Pressure in the Eye

I've been using Combigan for a little over a month and a half, and it's done an amazing job of reducing the pressure in my eyes. However, I have started to experience increased pain and stiffness in my muscles, which makes everyday tasks like getting out of bed or sitting in a chair for too long very painful. Has anyone else had this side effect?

4

Patient Review

10/12/2014

Combigan for Increased Pressure in the Eye

In combination with azopt, this treatment effectively lowered my eye pressure to a normal range.

4

Patient Review

2/23/2018

Combigan for Increased Pressure in the Eye

Combigan has been effective in reducing the pressure inside my eyes. However, I do feel tired after using it and my blood pressure drops for a few hours afterwards.

3.7

Patient Review

12/21/2013

Combigan for Increased Pressure in the Eye

Even though this medication decreased the pressure in my eye, I stopped using it because it felt like there was a piece of glass in my eye and it hurt every time I blinked. My eye is still scratchy and irritated even though I've discontinued use over a week ago.

3.7

Patient Review

2/6/2014

Combigan for Increased Pressure in the Eye

This medication was successful in reducing my intraocular pressure.

3.3

Patient Review

5/3/2014

Combigan for Wide-Angle Glaucoma

I experienced a significant drop in blood pressure and pulse after using Combigan. My average pulse would fall from 70 to 45-50 within two hours of application. I had to drink coffee frequently to avoid syncope. However, I developed severe allergic conjunctivitis after 8 months and my ophthalmologist advised me to discontinue use.

3.3

Patient Review

6/11/2014

Combigan for Increased Pressure in the Eye

Though it is effective, the level of fatigue it produces has become problematic. I will look for other options.

3.3

Patient Review

9/15/2021

Combigan for Increased Pressure in the Eye

It lowered my eye pressure, but it's quite pricey. My doctor recommended I switch to two separate drops which work just as well and cost much less.

3

Patient Review

2/19/2018

Combigan for Wide-Angle Glaucoma

I started taking Combigan under a doctor's care in April 2017. After about a month, I began feeling dizzy to the point where I couldn't stand without support. This light-headedness persisted for months. Additionally, after nine months of treatment with Combigan, my eye became very red and my eyelid drooped noticeably, changing my appearance significantly. These side effects were too much to bear so I stopped taking the medication, even though it was effectively lowering my eye pressure.

2.7

Patient Review

2/9/2018

Combigan for Wide-Angle Glaucoma

I developed macular edema after only three weeks of using this product! My doctor discontinued it immediately, but I'm still dealing with the aftermath.

2.3

Patient Review

6/11/2014

Combigan for Increased Pressure in the Eye

Unfortunately, this medication caused my fingers, ankles and knee to swell painfully. I had to stop taking it immediately.

2.3

Patient Review

10/25/2022

Combigan for Increased Pressure in the Eye

It did lower my blood pressure, but it was very expensive. I also experienced some pretty intense side effects, like redness and black rings around my eyes. Overall, I thought the medicine was too strong for me and stopped taking it.

1

Patient Review

2/14/2014

Combigan for Wide-Angle Glaucoma

My doctor recommended conbigan instead of timoptic xe. However, after only four days of using it, my eyes and cheeks became swollen and bloodshot. I also felt immense pain and had difficulty sleeping or seeing clearly. Needless to say, I stopped using the drops.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about combigan

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long can I use Combigan?

"eye drops expire four weeks after opening"

Answered by AI

Is Combigan a good eye drop?

"Researchers examined the effect of Combigan and brimonidine 0.2% plus a beta-blocker on increased eye pressure in children aged 2-16. They found that Combigan is safe and effective for this purpose."

Answered by AI

What is the drug Combigan used to treat?

"This combination medication lowered high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). By lowering high pressure inside the eye, it helps to prevent blindness. This product contains brimonidine and timolol."

Answered by AI

What is the generic for Combigan?

"- The U.S. Food and Drug Administration today approved brimonidine tartrate/timolol maleate ophthalmic solution 0.2%/0.5% (Alphagan P/Travatan Z), a generic version of AbbVie Inc.'s Combigan, for the reduction of intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

The U.S. Food and Drug Administration today approved a generic version of AbbVie Inc.'s Combigan, for the reduction of intraocular pressure in patients with ocular hypertension or open-angle glaucoma."

Answered by AI

Clinical Trials for Combigan

Image of Arizona State University in Phoenix, United States.

App-based Breathing Program for Migraine

18+
All Sexes
Phoenix, AZ

Migraine is one of the most common neurological disorders, characterized by recurrent headaches, sensitivity to light and movement, nausea, and autonomic dysregulation. Although mind-body interventions like biofeedback have shown their efficacy, they remain underutilized due to barriers such as transportation, time constraints, lack of awareness, stigma, and cost. A targeted approach to enhancing HRV is HRV biofeedback (HRVB), a technique using visual or auditory feedback to help people regulate HRV through slow-paced breathing and positive emotional regulation to promote ANS balance and emotional resilience. Investigators will conduct a remotely delivered pilot RCT of an 8-week, 10 min/day, novel app-based HRVB intervention compared to a sham control intervention (matching intervention time and attention with no biofeedback component) in adult with chronic migraine. Investigators hypothesize data collected from the study will: a) support the feasibility and acceptability of the remotely delivered app-based HRVB intervention among adults with chronic migraine, and b) provide insights into refining the intervention by examining patterns of change in migraine and psychological outcomes from pre- to post-intervention.

Waitlist Available
Online Trial

Arizona State University

Have you considered Combigan clinical trials?

We made a collection of clinical trials featuring Combigan, we think they might fit your search criteria.
Go to Trials
Image of Johns Hopkins Medicine in Baltimore, United States.

Embolization for Migraine

18 - 80
All Sexes
Baltimore, MD

This study is to test the safety and feasibility of a procedure called embolization of the middle meningeal arteries (MMA), using a product called Onyx. Embolization creates a plug in the arteries. MMA embolization with Onyx is not approved for use in patients with migraines, but is currently used in patients with subdural hematomas. The FDA is allowing the use of Onyx in this study. It is thought that by using Onyx to block the middle meningeal arteries, the amount of migraine-causing substances which are released into the brain's bloodstream will be reduced. The company that manufactures Onyx, Medtronic, is providing the supplies for this study. Participants will be in the study for about 8 months after enrolling, including 6 months of follow up after the procedure. The participants will be asked to complete a daily headache diary and continue the participant's regular migraine medications. Participants will also have several clinic visits and be asked to provide blood samples for research.

Waitlist Available
Has No Placebo

Johns Hopkins Medicine

Risheng Xu, MD, PhD

Medtronic

Have you considered Combigan clinical trials?

We made a collection of clinical trials featuring Combigan, we think they might fit your search criteria.
Go to Trials

Have you considered Combigan clinical trials?

We made a collection of clinical trials featuring Combigan, we think they might fit your search criteria.
Go to Trials